New pill aims to melt liver fat in 12 weeks

NCT ID NCT07308548

Recruiting now Disease control Sponsor: Hinova Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 21, 2026 · Updated 11 times

Summary

This study tests an experimental pill, HP515, in 80 adults with non-alcoholic fatty liver disease (NAFLD). The main goal is to see if it reduces liver fat over 12 weeks using MRI scans. Participants must have at least 10% liver fat and be aged 18-65. The trial also checks safety and how the drug works in the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NAFLD - NON-ALCOHOLIC FATTY LIVER DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing Tsinghua Changgung Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 102218, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Chengdu Seventh People's Hospital
RECRUITING

Chengdu, Sichuan, 610041, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

NAFLD - NON-ALCOHOLIC FATTY LIVER DISEASE